StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
315640.KQ$2590.00-8.48%
Fair $2590.00+0.0%

315640.KQ

DEEPNOID Inc.

Healthcare / Health Information ServicesKOSDAQ

$2590.00

-240.00 (-8.48%)

Fairly Valued+0.0%Fair Value $2590.00Fund rank 31/100 · Data gapFallback financials|
SA 23/D
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 24%

FCF escenarios

weak_data · normalized FCF $-7.2B · quality 73.0/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 37/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

23/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -37.7%, below the 5% threshold
Thesis & Journal · 315640.KQLocal privado en este navegador · DEEPNOID Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$63.2B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-37.7%

↓

Gross Margin

64.1%

↑

Debt/Equity

0.24

↑
52-Week Range$2590
$2575$7000

TradingView lightweight chart

315640.KQ price, volumen y niveles de valoración

Último $2,590Periodo -89.1%
Fair value: $2,590

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+32.9%

FCF CAGR

—

FCF margin

-96.9%

FCF / Net income

0.67x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $7.47B · net income $-10.75B · FCF $-7.24B

2022-FY → 2025-FY

Gross margin

64.1%+15.5% pts

Operating margin

-141.3%+52.3% pts

Net margin

-143.8%+23.8% pts

FCF margin

-96.9%+36.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$7.47B$7.47B$10.85B$1.93B$3.18B
Net Income$-10.75B$-10.75B$-9.08B$-6.74B$-5.33B
EBITDA$-9.52B$-9.52B$-8.05B$-5.98B$-4.61B
EPS-472.00-472.00-383.07-158.85-245.39
Gross Margin64.1%64.1%9.5%41.9%48.7%
Operating Margin-141.3%-141.3%-93.1%-348.0%-193.6%
Net Margin-143.8%-143.8%-83.7%-348.5%-167.7%
Balance Sheet
Debt/Equity0.240.240.390.010.06
Current Ratio8.068.06———
Cash Flow
Free Cash Flow$-7.24B$-7.24B$-23.30B$-5.59B$-4.23B
Returns
ROE-37.7%-37.7%-47.7%-24.8%-53.5%
Valuation
P/B2.072.077.2835.1111.32
Growth & Yield
Revenue Growth-31.1%-31.1%461.1%-39.2%—
EPS Growth-23.2%-23.2%-141.1%35.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -60.3%

Total return

-60.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-383.07 → -472.00

Residual

-60.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-60.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.